Tue, Sep 16, 2014, 10:05 AM EDT - U.S. Markets close in 5 hrs 55 mins

Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • carrivechio carrivechio Jan 4, 2013 12:35 PM Flag

    Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

    Search: Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

    Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J.
    Novartis Pharmaceuticals Corporation, Florham Park, NJ

    Abstract

    In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies. We suggest that progression-free survival is an appropriate efficacy end point in many types of cancer, specifically those for which OS is expected to be prolonged and for which subsequent treatments are expected to affect OS.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From time to time I have pointed out that you cut/paste/post things that don't really support your argument. To be honest, you seem to have learned nothing from my efforts to be helpful. e.g.:

      You cite "...We suggest that progression-free survival is an appropriate efficacy end point in many types of cancer, specifically those for which OS is expected to be prolonged..."

      The importance of 6/12 week PFS on our PIII trials has repeatedly been explained as being meaningful BECAUSE survival IS NOT expected to be prolonged and that PFS is a relatively accurate OS indicator when the historical OS is short.

      You might want to think about that for a minute or two.

      You're welcome.

    • Your point is what again? Your post just reiterates what I done tol ya already. PFS may be used when OS is a) affected by subsequent treatments thus invalidating the results and b) when OS is PROLONGED. Posting random blurbs is meaningless. The median os in THIS trial is 4.9 months you will have os data within months of pfs. PDFs can be used in trials where patients aren't even expected to die so os is not even a viable endpoint. Acne, lupus, diabetes, macular degeneration etc. saying PDFs is a goals std just makes you look silly.

      • 1 Reply to rationalthought11
      • irrational_thought whose real name is Paul Springer wrote: "NO compound or biologic has ever received approval based on PFS."

        I have just proved you ENTIRELY WRONG!

        Furthermore according to the recently published work of Petrelli and Barni appearing in this month's edition of Annals of Oncology 2013 Jan;24(1):186-92 and entitled "Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer" they found that "improvements in PFS are strongly associated with improvements in OS." and that "PFS may be an appropriate surrogate for OS."

    • Search: U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)

      First Treatment to Demonstrate Superior Benefit in a Phase 3 Study Compared with Another Targeted Agent in Advanced RCC

      January 27, 2012 01:33 PM Eastern Time

      NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

    • On July 20, 2012, the U.S. Food and Drug Administration approved everolimus tablets (Afinitor, Novartis Pharmaceuticals Corporation) for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.

      The median progression-free survival (PFS) by investigator assessment at the time of the final PFS analysis was 7.8 and 3.2 months in the everolimus and placebo arms, respectively.

      The final analysis of OS is expected to occur in June 2014.

 
ONCY
1.25-0.01(-0.79%)10:03 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.